Technology
Potentially disruptive technologies
We have three highly differentiated technologies focused on next generation anthracycline, immune/transcription modulators and metabolism/glycosylation inhibitors.
Pipeline
Attacking the most difficult cancers & viruses
We are developing treatments for highly resistant viruses and cancers such as acute myeloid leukemia; cutaneous T-cell lymphoma, a deadly form of skin cancer; pancreatic cancer, glioblastoma, brain tumors; and COVID-19.
Partnerships & Collaborations
Relationships with world-class cancer centers
Critical to our efforts is leveraging our continued collaborations and partnerships with leading cancer centers like MD Anderson Cancer Center, Emory University, the Mayo Clinic and others.
Priority Development Pipeline
Follow-on Development Pipeline
Annamycin
The Next Generation Anthracycline
Annamycin is a unique next-generation liposome formulated anthracycline that has been designed to eliminate cardiotoxicity and avoid the multidrug resistance mechanisms that often defeat currently approved anthracyclines.
WP1066
An Immune/Transcription Modulator
WP1066 is one of several Immune/Transcription Modulators, designed to stimulate the immune response to tumors by inhibiting the errant activity of Regulatory T-Cells while also inhibiting key oncogenic transcription factors, including p-STAT3, c-Myc and HIF-1α.
WP1122
A Metabolism/Glycosylation Inhibitor
WP1122 is a prodrug of a well-known glucose decoy called 2-deoxy-D-glucose, or 2-DG, which enables increased cellular uptake, increased drug half-life and, importantly, an increased ability to cross the blood brain barrier, enabling greater uptake in the brain.